ResMed Quarterly Filing Shows Cash and Debt Fell
RMD: $33.46 -5.77% · MC: $48.0B
ResMed’s quarterly filing shows cash and equivalents fell to about US$1 billion at the end of September, from nearly US$1.5 billion at the end of June. Short- and long-term debt combined fell to about US$410 million from US$659 million. The company previously reported that it returned more than US$1 billion to shareholders through buybacks and dividends during the quarter, supported by cash flow and proceeds from the MatrixCare sale.

Comments